BioSpace News Archive

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a treatment for patients with type 2 diabetes, in a late-breaking poster presentation at the 2023 American Diabetes Association (ADA) 83rd Scientific Sessions, to be held June 23 – 26, 2023 in San Diego, CA.

Lisata Therapeutics, Inc. announces its participation in the upcoming Sequire Investor Summit to be held April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is taking place on April 25 – 26, 2023.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) announced today the first ever data demonstrating the utility of Actimab-A to depleted myeloid derived suppressor cells (MDSCs), which are ubiquitously present within the solid tumor microenvironment as well as blood cancers.

Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation in the biopharmaceutical industry.

Mirion Technologies, Inc. (NYSE: MIR) (“Mirion”) (“Company”) announced today that it will release its financial results for the first quarter of 2023 on Wednesday, May 3, 2023.

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 SPOTLIGHT Study of PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer.

Schrödinger, Inc. today reported that on April 14, 2023, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSU) with respect to 1,800 shares of the company’s common stock to one newly hired employee.

Vistagen today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C.

Orange Biomed—a healthcare startup with cutting-edge diabetes management technology—announced its U.S. launch today with a mission to fill critical testing gaps for people with pre-diabetes and diabetes.